Select Equity Group L.P. Buys 107,455 Shares of Zoetis Inc. (NYSE:ZTS)

Select Equity Group L.P. raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 130.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 189,703 shares of the company's stock after purchasing an additional 107,455 shares during the quarter. Select Equity Group L.P.'s holdings in Zoetis were worth $30,908,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis in the fourth quarter worth $30,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis in the fourth quarter worth $44,000. Finally, Asset Planning Inc acquired a new position in shares of Zoetis in the fourth quarter worth $58,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS stock traded down $0.82 during mid-day trading on Thursday, reaching $160.62. 699,479 shares of the stock traded hands, compared to its average volume of 3,039,197. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The business has a 50-day moving average of $156.58 and a two-hundred day moving average of $165.05. The firm has a market capitalization of $71.51 billion, a PE ratio of 29.35, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period in the prior year, the company earned $1.38 earnings per share. The business's quarterly revenue was up 1.4% compared to the same quarter last year. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ZTS shares. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Piper Sandler upped their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.